These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36914591)

  • 21. The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study.
    Brown JM; Siddiqui M; Calhoun DA; Carey RM; Hopkins PN; Williams GH; Vaidya A
    Ann Intern Med; 2020 Jul; 173(1):10-20. PubMed ID: 32449886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.
    Calhoun DA; White WB; Krum H; Guo W; Bermann G; Trapani A; Lefkowitz MP; Ménard J
    Circulation; 2011 Nov; 124(18):1945-55. PubMed ID: 21986283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of variation in CYP11B1 and CYP11B2 on corticosteroid phenotype and hypothalamic-pituitary-adrenal axis activity in hypertensive and normotensive subjects.
    Freel EM; Ingram M; Wallace AM; White A; Fraser R; Davies E; Connell JM
    Clin Endocrinol (Oxf); 2008 May; 68(5):700-6. PubMed ID: 17980006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Moxonidine on the Aldosterone/Renin Ratio in Healthy Male Volunteers.
    Ahmed AH; Gordon RD; Ward G; Wolley M; McWhinney BC; Ungerer JP; Stowasser M
    J Clin Endocrinol Metab; 2017 Jun; 102(6):2039-2043. PubMed ID: 28324033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of aldosterone synthase CYP11B2 (-344C/T) gene polymorphism with essential hypertension and left ventricular hypertrophy in the Egyptian population.
    Abdel Ghafar MT
    Clin Exp Hypertens; 2019; 41(8):779-786. PubMed ID: 30561227
    [No Abstract]   [Full Text] [Related]  

  • 26. Normoaldosteronemic aldosterone-producing adenoma: immunochemical characterization and diagnostic implications.
    Rossi GP; Gioco F; Fassina A; Gomez-Sanchez CE
    J Hypertens; 2015 Dec; 33(12):2546-9. PubMed ID: 26536091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aldosterone suppression with dopamine infusion in low-renin hypertension.
    Holland OB; Thomas C; Brown H; Schindewolf D; Hillier Y; Gomez-Sanchez C
    J Clin Invest; 1983 Sep; 72(3):754-66. PubMed ID: 6309909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of physiological levels of atrial natriuretic peptide on hormone secretion: inhibition of angiotensin-induced aldosterone secretion and renin release in normal man.
    Cuneo RC; Espiner EA; Nicholls MG; Yandle TG; Livesey JH
    J Clin Endocrinol Metab; 1987 Oct; 65(4):765-72. PubMed ID: 2821056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aldosterone synthase gene variation and adrenocortical response to sodium status, angiotensin II and ACTH in normal male subjects.
    Kennon B; Ingram MC; Friel EC; Anderson NH; MacKenzie SM; Davies E; Shakerdi L; Wallace AM; Fraser R; Connell JM
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):174-81. PubMed ID: 15272911
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Promoter variants of aldosterone synthase gene (CYP11B2) and salt-sensitivity of blood pressure].
    Wrona A; Widecka K; Adler G; Czekalski S; Ciechanowicz A
    Pol Arch Med Wewn; 2004 Feb; 111(2):191-7. PubMed ID: 15230231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin.
    Takeda Y; Miyamori I; Yoneda T; Hatakeyama H; Inaba S; Furukawa K; Mabuchi H; Takeda R
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2797-800. PubMed ID: 8768832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypertension and Lorundrostat: Key Discoveries From the TARGET-HTN Trial.
    Irfan H; Ahmed A; Nawani KD
    Curr Probl Cardiol; 2024 Jan; 49(1 Pt C):102144. PubMed ID: 37858848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A biallelic gene polymorphism of CYP11B2 predicts increased aldosterone to renin ratio in selected hypertensive patients.
    Nicod J; Bruhin D; Auer L; Vogt B; Frey FJ; Ferrari P
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2495-500. PubMed ID: 12788845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aldosterone synthase gene (CYP11B2) C-344T polymorphism in Caucasians from the Berlin Salt-Sensitivity Trial (BeSST).
    Brand E; Schorr U; Ringel J; Beige J; Distler A; Sharma AM
    J Hypertens; 1999 Nov; 17(11):1563-7. PubMed ID: 10608469
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension.
    Awosika A; Cho Y; Bose U; Omole AE; Adabanya U
    Expert Opin Investig Drugs; 2023; 32(11):985-995. PubMed ID: 37883217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic alterations in patients with primary aldosteronism.
    Takeda Y
    Hypertens Res; 2001 Sep; 24(5):469-74. PubMed ID: 11675938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aldosterone synthase gene (CYP11B2) C-344T polymorphism, plasma aldosterone, renin activity and blood pressure in a multi-ethnic population.
    Barbato A; Russo P; Siani A; Folkerd EJ; Miller MA; Venezia A; Grimaldi C; Strazzullo P; Cappuccio FP
    J Hypertens; 2004 Oct; 22(10):1895-901. PubMed ID: 15361760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The mechanism of low-renin hypertension: aldosterone response to sodium restriction and upright posture, angiotensin II, ACTH and potassium in patients with hypertension.
    Saito I; Saruta T; Nakamura R; Misumi J; Kondo K; Matsuki S
    Jpn Circ J; 1976 Aug; 40(8):911-9. PubMed ID: 184308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of ACTH and Other Hormones in the Regulation of Aldosterone Production in Primary Aldosteronism.
    El Ghorayeb N; Bourdeau I; Lacroix A
    Front Endocrinol (Lausanne); 2016; 7():72. PubMed ID: 27445975
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The constant plasma 18-hydroxycorticosterone to aldosterone ratio: an expression of the efficacy of corticosterone methyloxidase type II activity in disorders with variable aldosterone production.
    Kater CE; Biglieri EG; Rost CR; Schambelan M; Hirai J; Chang BC; Brust N
    J Clin Endocrinol Metab; 1985 Feb; 60(2):225-8. PubMed ID: 2981240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.